The premium pricing to last close provides a short-term cushion, but the small absolute raise ($1.685M net) is insufficient to fund Phase IIa Parkinson's trial completion and the PharmAla ALA-002 deal ($1.5M cash at close + $600K escrow already deposited). Monitor for further dilutive events — the Yorkville SEPA convertible notes at $1.50/share are deeply out-of-the-money given the current ~$0.21 stock price, creating overhang. The going concern qualification remains unresolved. Watch for Nasdaq compliance risk if stock stays below $1.00.
Price Chart
Executive Summary
Jupiter Neurosciences has priced a registered direct offering of 7,142,858 shares of common stock at $0.28 per share, raising gross proceeds of $2 million. The offering is priced at a ~36.6% premium to the last closing price of $0.2050, but the net proceeds of ~$1.685M provide only modest working capital runway for a clinical-stage biotech with a going concern qualification. The company also disclosed a non-binding term sheet for a potential licensing deal with PharmAla Biotech involving a $3.33M upfront consideration and $600K escrow deposit, adding another layer of execution risk and cash drain.
Key Facts
- Offering 7,142,858 shares at $0.28/share for gross proceeds of $2,000,000.24
- Net proceeds of ~$1.685M after placement agent fees of $140,000 and estimated offering expenses of $175,000
- Offering price is a 36.6% premium to the $0.2050 last sale price on May 20, 2026
- Pro forma shares outstanding increase to 43,424,110 from 36,281,252 — 19.7% dilution
- As of March 31, 2026, net tangible book value was negative $(0.08)/share; after offering improves to negative $(0.03)/share
- Dilution to new investors of $0.31/share relative to offering price
- Existing auditor's report includes going concern explanatory paragraph for FY2025 and FY2024
- Company has approximately $6.0M in convertible notes outstanding from Yorkville (Oct/Dec 2025), convertible at $1.50/share with 8% interest (18% default)
- Non-binding term sheet signed May 19, 2026 to acquire U.S. rights to PharmAla's ALA-002 for $3.33M upfront ($1.5M cash + $1.83M equity) plus milestones and 3% royalty; $600K placed in escrow
- 30-day lock-up on further equity issuance; 1-year prohibition on variable rate transactions
Financial Impact
Immediate dilution of ~19.7% to existing shareholders; net proceeds of $1.685M represent less than 5 quarters of cash burn for a clinical-stage company with no meaningful product revenue and $6M in convertible notes due Oct 2026
Risk Factors
- Going concern qualification in audited financials — negative tangible book value persists post-offering
- Insufficient capital to fund Phase IIa Parkinson's trial and PharmAla license simultaneously
- Yorkville convertible notes ($6M principal, 8% interest, mature Oct 2026) are deep underwater at current stock price, creating massive dilution if converted or forcing cash repayment
- PharmAla term sheet is non-binding with 90-day exclusivity — $600K escrow at risk if deal fails
- At $7M market cap, low liquidity and penny stock risk if Nasdaq listing requirements not met
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-024740 |
| Document: 0001493152-26-024740-index-headers.html | 0001493152-26-024740 |
| Document: 0001493152-26-024740-index.html | 0001493152-26-024740 |
| Document: 0001493152-26-024740.txt | 0001493152-26-024740 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13G/A | $2.88 | awaiting T+5 | — | $2.86 (−0.69%) |
Sep 24, 2026 4w ago | S-3 | $2.67 $2.55 | ▲ +4.49% | ▲ +4.27% | $2.86 (−7.12%) |
Sep 22, 2026 4w ago | SC 13G | $2.98 $2.58 | ▼ −13.42% | ▼ −12.24% | $2.86 (−4.03%) |
Aug 28, 2026 8w ago | 8-K | $3.54 $3.08 | ▲ +12.99% | ▲ +12.85% | $2.86 (+19.21%) |
Aug 27, 2026 8w ago | 8-K | $4.89 $3.26 | ▲ +33.33% | ▲ +33.60% | $2.86 (+41.51%) |
Aug 24, 2026 9w ago | 8-K | $5.17 $3.35 | ▲ +35.20% | ▲ +34.66% | $2.86 (+44.68%) |
Aug 24, 2026 9w ago | 8-K | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Aug 24, 2026 9w ago | 424B5 | $5.66 $3.54 | ▲ +37.46% | ▲ +37.92% | $2.86 (+49.47%) |
Jul 27, 2026 13w ago | 8-K | $0.1135 $0.1000 | ▲ +11.89% | ▲ +14.41% | $2.86 (−2419.82%) |
Jul 21, 2026 13w ago | Press Release | $0.1697 $0.1097 | ▼ −35.36% | ▼ −34.36% | $2.86 (+1585.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers